Evidence map›Paper›PMID 40351316›Full record

ArticleFrontiers in microbiology2025

Design and construction of a fast synthetic modified vaccinia virus Ankara reverse genetics system for advancing vaccine development.

Zhiqiang Gao, Busen Wang, Tianyu Liu, Zhenghao Zhao, Jinghan Xu, Xiaofan Zhao, Zhe Zhang, Zuyuan Jia, Yilong Yang, Shipo Wu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhiqiang Gao *Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Busen Wang *Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Tianyu LiuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Zhenghao ZhaoLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Jinghan XuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Xiaofan ZhaoLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Zhe ZhangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Zuyuan JiaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Yilong YangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Shipo WuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Wei ChenLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Lihua HouLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The modified vaccinia virus Ankara (MVA) is approved for use as a smallpox and monkeypox virus vaccine and was also designed as a popular recombinant viral vector for vaccine development and gene therapy. However, the extensive genomes of poxviruses present a significant challenge for the development of recombinant viral vaccines; therefore, it is essential to establish a user-friendly

Indexed as

modified vaccinia virus Ankara (MVA)rescuereverse genetic systemviral genomesviral vector vaccine

Identifiers

PMID40351316
PMCPMC12061933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.